<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04293159</url>
  </required_header>
  <id_info>
    <org_study_id>University of Salerno</org_study_id>
    <nct_id>NCT04293159</nct_id>
  </id_info>
  <brief_title>Effect of Probiotic on Constipation in Patients With Parkinson's Disease</brief_title>
  <official_title>Effect of Probiotic on Constipation and on Neuropsychological Performance in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Salerno</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roberto Erro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maria Teresa Pellecchia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Antonella Santonicola</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carolina Ciacci</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Salerno</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to collect data for the assessment of the Lactobacillus casei DG
      (Enterolactis ®duo) effect on constipation and on neuropsychological performance
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to collect data for the assessment of the Lactobacillus casei DG
      (Enterolactis® duo) effect on overall abdominal pain, bowel movements and other abdominal
      symptoms and on neuropsychological performance in patients with Parkinson's Disease. The
      investigators suppose that, due to the immunomodulatory action of probiotics, overall
      neuropsychological function will improve as well as due also to prebiotic abdominal symptoms
      will decrease following consumption of Lactobacillus casei DG (Enterolactis® duo).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>satisfaction with therapy</measure>
    <time_frame>12 weeks</time_frame>
    <description>A &quot;satisfaction with therapy&quot; score (on a 7-point Likert scale: 1 = extremely dissatisfied, 2 = very dissatisfied, 3 = dissatisfied, 4 = partially satisfied, 5 = satisfied, 6 = very satisfied, 7 = extremely satisfied)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement after treatment</measure>
    <time_frame>12 WEEKS</time_frame>
    <description>&quot;Improvement after treatment&quot; was evaluated with a global rating-of-change scale (−7 to +7: −7 = extremely worsened, 0 = unchanged,
+7 = extremely improved). &quot;Improvement after treatment&quot; was defined by an increase in the global rating-of-change scale of ≥2 points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neuropsychological function</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Non-Motor Symptoms Scale (NMSS) is a 30-item rater-based scale that assesses a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions. The scale can be used for patients at all stages of PD.The total NMSS score ranges from 0 to 360, the worst.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Unified Parkinson Disease Rating Scale (UPDRS, italian version)</measure>
    <time_frame>12 WEEKS</time_frame>
    <description>the Unified Parkinson Disease Rating Scale (UPDRS, italian version). The UPDRS is a rating tool used to gauge the course of Parkinson's disease in patients. A score of 199 on the UPDRS scale represents the worst (total disability) with a score of zero representing (no disability); The Non-motor-symptoms scale (NMSS, italian version)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>M-PAC SYM</measure>
    <time_frame>12 WEEKS</time_frame>
    <description>M-PAC-SYM)5 The Patient Assessment of Constipation Symptoms (scoring from 0 = absent to 4 = very strong)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Lactobacillus casei DG (Enterolactis duo®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus casei DG (Enterolactis duo®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus casei DG (Enterolactis duo®)</intervention_name>
    <description>Lactobacillus casei DG (Enterolactis duo®)</description>
    <arm_group_label>Lactobacillus casei DG (Enterolactis duo®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A positive diagnosis of functional constipation or Irritable Bowel Syndrome -subtype
             constipation according to Rome IV criteria.

          -  Negative for colon cancer screening

          -  Negative relevant additional screening or consultation whenever appropriate.

          -  Ability of conforming to the study protocol.

          -  Stable treatment for Parkinson's disease

        Exclusion Criteria:

          -  Presence of any other relevant organic, systemic or metabolic disease (particularly
             significant history of cardiac, renal, oncology, endocrinology, metabolic or hepatic
             disease), or abnormal laboratory values that will be deemed clinically significant on
             the basis of predefined values a part from Parkinson's disease

          -  Ascertained intestinal organic diseases, including ascertained celiac disease or
             inflammatory bowel diseases (Crohn's disease, ulcerative colitis, diverticular
             disease, infectious colitis, ischemic colitis, microscopic colitis).

          -  Previous major abdominal surgeries.

          -  Inability to conform with protocol.

          -  Recent history or suspicion of alcohol abuse or drug addiction.

          -  Previous participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PAOLA IOVINO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Salerno</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PAOLA IOVINO, MD</last_name>
    <phone>+39 3357822672</phone>
    <email>piovino@unisa.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aou Sangiovanni E Ruggi D'Aragona</name>
      <address>
        <city>Salerno</city>
        <zip>84000</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Longo K, Cozzolino A, Giordano F, De Rosa A, De Michele G, Pellecchia MT, Barone P. Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):14-7. doi: 10.1136/jnnp-2012-303419. Epub 2012 Sep 19.</citation>
    <PMID>22993448</PMID>
  </results_reference>
  <results_reference>
    <citation>Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2015 Jun;14(6):625-39. doi: 10.1016/S1474-4422(15)00007-1. Review.</citation>
    <PMID>25987282</PMID>
  </results_reference>
  <results_reference>
    <citation>Martínez-Martínez MI, Calabuig-Tolsá R, Cauli O. The effect of probiotics as a treatment for constipation in elderly people: A systematic review. Arch Gerontol Geriatr. 2017 Jul;71:142-149. doi: 10.1016/j.archger.2017.04.004. Epub 2017 Apr 14. Review.</citation>
    <PMID>28467916</PMID>
  </results_reference>
  <results_reference>
    <citation>Bellini M, Usai-Satta P, Bove A, Bocchini R, Galeazzi F, Battaglia E, Alduini P, Buscarini E, Bassotti G; ChroCoDiTE Study Group, AIGO. Chronic constipation diagnosis and treatment evaluation: the &quot;CHRO.CO.DI.T.E.&quot; study. BMC Gastroenterol. 2017 Jan 14;17(1):11. doi: 10.1186/s12876-016-0556-7.</citation>
    <PMID>28088179</PMID>
  </results_reference>
  <results_reference>
    <citation>Neri L, Iovino P; Laxative Inadequate Relief Survey (LIRS) Group. Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation-predominant irritable bowel syndrome and functional constipation. Neurogastroenterol Motil. 2016 Apr;28(4):581-91. doi: 10.1111/nmo.12758. Epub 2016 Feb 12.</citation>
    <PMID>26867677</PMID>
  </results_reference>
  <results_reference>
    <citation>Cappello C, Tremolaterra F, Pascariello A, Ciacci C, Iovino P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): effects on symptoms, colonic transit and quality of life. Int J Colorectal Dis. 2013 Mar;28(3):349-58. doi: 10.1007/s00384-012-1552-1. Epub 2012 Aug 12.</citation>
    <PMID>22885882</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Salerno</investigator_affiliation>
    <investigator_full_name>PAOLA IOVINO</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>constipation</keyword>
  <keyword>Parkinson's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

